\
&
Contact us
\
&
Contact us
Starts in 3 weeks from now
LocationRoyal Institute for Cultural Heritage (KIK-IRPA), Brussels
ProgrammesThis event hosted by the Royal Institute for Cultural Heritage (KIK-IRPA) in Brussels is an initiative from three projects funded by Horizon Europe: MOXY, GreenArt, and GoGreen united in a Green Cluster for Science and Conservation Research.
This strategic policy meeting brings together Green Cluster Project participants, European Commission policymakers, and leading practitioners in conservation, cultural heritage, sustainability, and industrial stakeholders to explore how green conservation can be more effectively integrated into European cultural heritage policy. The day aligns the work of the Green Cluster with European policy and industry, highlighting opportunities for integration, implementation, and support based on green innovation and technological developments.
Fore more information on this event and programme please visit the webpage of the event.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
